Proximagen Neuroscience acquires Cambridge Biotechnology Ltd.

Proximagen Neuroscience completed the acquisition of Cambridge Biotechnology Ltd and several drug development programs from Biovitrum AB. Proximagen is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for diseases of the central nervous system whose current programs work to improve the quality of life for neurodegenerative disease patients. Its pipeline currently includes an array of partnered and un-partnered drug 2 candidate programs that address unmet medical needs of patients with neurodegenerative disease.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail